Retrospective Evaluation of Cutaneous Malignant Melanoma Patients in the Eastern Black Sea Region in Terms of Tumor Thickness and Survival: Cohort Study Doğu Karadeniz Bölgesi’ndeki Kutanöz Malign Melanom Hastalarının Tümör Kalınlığı ve Sağkalım Açısından Retrospektif Değerlendirilmesi: Kohort Çalışması

Creative Commons License


Turkiye Klinikleri Journal of Medical Sciences, vol.43, no.2, pp.178-184, 2023 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 2
  • Publication Date: 2023
  • Doi Number: 10.5336/medsci.2022-95110
  • Journal Name: Turkiye Klinikleri Journal of Medical Sciences
  • Journal Indexes: Scopus, CAB Abstracts, CINAHL, Veterinary Science Database
  • Page Numbers: pp.178-184
  • Keywords: Melanoma, survival
  • Karadeniz Technical University Affiliated: Yes


Objective: The aim of our study is to investigate the malignant melanoma patient profile of the Eastern Black Sea region, which has a different appearance than other regions of our country both geo-graphically and physically, and to reveal the relationship between the survival times of these patients and tumor thickness. Material and Methods: Our study is a clinical study and a retrospective cohort study. 122 patients who were diagnosed with malignant melanoma International Classification of Diseases (ICD) in the Department of Plastic, Reconstructive and Aesthetic Surgery of Karadeniz Tecnical University Farabi Hospital between 2007 and 2018 were included in our study. Non-cutaneous malignant melanoma, uveal melanoma, metastatic melanoma of unknown primary and mucosal melanomas diagnosed as malignant melanoma ICD were excluded from the study. In addition, malignant melanoma in situ cases and cases with incomplete data were not included in the study. In the survival calculations, 81 patients who were followed up for 5 years were evaluated and statistical analysis was made with the SPSS program. Results: The most common localization of malignant melanoma masses was lower extremity (n=58, 47.5%). The most common subtype was nodular malignant melanoma(n=50, 41.0%). When calculating survival rates, deaths from non-melanoma causes were not included. During the follow-up, 45 (55.6%) of 81 patients were found to have died and 36 (44.4%) were found to be alive. 88% of the patients were still alive at the end of the first year after diagnosis, 75% at the end of the 2nd year, and 48% at the end of the 5th year. At the end of 5 years, 57% of the patients with Breslow thickness ≤4 mm were still alive, while 39% of the patients with >4 mm were still alive. Conclusion: Unlike studies abroad, malignant melanoma in our country diagnosis is delayed. Early diagnosis modalities should be developed to achieve better survival rates.